Table 1

Baseline Characteristics of Patients With Normal Versus Abnormal MPS

Patients With Normal MPS
(n = 313)
Patients With Abnormal MPS
(n = 87)
p Value
Age, yrs63 ± 865 ± 70.01
Male6584<0.001
Diabetes duration, yrs10 ± 713 ± 90.0019
BMI, kg/m231 ± 631 ± 60.92
End-organ damage
 Retinopathy22290.22
 Polyneuropathy46580.06
 Nephropathy44550.08
 Autonomic neuropathy42600.0075
 Peripheral artery disease1129<0.0001
 Stroke/TIA991.00
Patients with ≥1 of listed end-organ damages86920.19
Smoking18320.0047
Shortness of breath (NYHA functional class I–III)45530.24
Resting heart rate, beats/min74 ± 1177 ± 130.06
Systolic blood pressure, mm Hg137 ± 19141 ± 170.02
HbA1c7.3 ± 1.27.4 ± 1.30.39
Microalbuminuria44540.14
Creatinine, μmol/l75 ± 2385 ± 25<0.001
Total cholesterol, mmol/l4.7 ± 1.04.5 ± 1.10.27
LDL cholesterol, mmol/l2.5 ± 0.92.4 ± 1.00.19
BNP, ng/l, median34490.02
Antiplatelet drugs50630.03
Oral anticoagulants460.83
Beta blocker31360.49
Calcium antagonist23330.07
Statins55660.10
ACE-I/ARB74840.10
Diuretics46590.05
Oral glucose-lowering therapy79840.38
Insulin50511.00
ECG q-waves5.33.80.22
Ergometry: exercise/pharmacologic/combined81/4/1557/15/28<0.0001
Symptoms during ergometry12160.48
ECG changes during ergometry526<0.0001
SSS/% myocardium, median08/11.8<0.0001
SDS/% myocardium ischemic, median03/4.4<0.0001
Left ventricular ejection fraction, %60 ± 951 ± 14<0.001

Values are mean ± SD or %.

ACE-I/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BMI = body mass index; BNP = brain natriuretic peptide; ECG = electrocardiogram; HDL = high-density lipoprotein; HbA1c = hemoglobin A1c; MPS = myocardial perfusion single-photon emission computed tomography; NYHA = New York Heart Association; SDS = summed difference score; SSS = summed stress score; TIA = transient ischemic attack.

  • p values were calculated with the use of a Mann-Whitney U test for quantitative variables and a chi-square test for qualitative variables.